Last reviewed · How we verify
anti-ILT3 CAR-T — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
anti-ILT3 CAR-T (anti-ILT3 CAR-T) — Carbiogene Therapeutics Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-ILT3 CAR-T TARGET | anti-ILT3 CAR-T | Carbiogene Therapeutics Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-ILT3 CAR-T CI watch — RSS
- anti-ILT3 CAR-T CI watch — Atom
- anti-ILT3 CAR-T CI watch — JSON
- anti-ILT3 CAR-T alone — RSS
Cite this brief
Drug Landscape (2026). anti-ILT3 CAR-T — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-ilt3-car-t. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab